While there has been progress in pre-clinical and clinical development of vaccines against LASV, there are currently no approved therapeutics or anti-viral drugs available for the treatment of LF. The high disease burden in West Africa, along with the logistical difficulties in deploying vaccines t...
Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or
Available online at: https://www.gavi.org/vaccineswork/covid-19-vaccine-race [Last accessed: July 8, 2021]). Vaccine typeInstituteCountry Viral vector vaccine Beijing wantai biological pharmacy China Protein subunit vaccine West china hospital of sichuan university China RNA vaccine Arcturus/duke-...
Current COVID-19 vaccines present the spike protein in very different ways to the immune system, and two main categories have to be discerned. The first category consists of mRNA and adenoviral vector vaccines (herein referred to as genetic vaccines, sections: “Genetic vaccines—general, “mRNA...
Table 7 Current list of available vaccines and their efficiency Full size table mRNA Vaccines BNT162b2 BNT162b2 mRNA-based vaccine was developed by the Pfizer BioNtech, Fousun pharma. BioNtech is the first company to register for the FDA approval of their candidate COVID-19 vaccine. BNT162b2...
Data from a survey of 343 oncologists from 28 countries with a self-reported COVID-19 outbreak (99.7%) reported that PPE was available to all participants (Ürün et al., 2020). It should be noted that the type of PPE used by the participating oncologists varied, and while 89.8% ...
Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19 Dinah V. Parums, DOI: 10.12659/MSM.935624 Med Sci Monit 2021; 27:e935624 633398722 HTML version available soon Related articlesOrder reprintsShare articleShare by email 01 March 2025 :Editorial ...
On January 11, the United States reported a record-breaking 1.35 million new COVID-19 infections, shattering the previous record set just eight days before. The sky-high case rate—roughly four times higher than numbers of daily infections seen last Janu
Why do we need a T-cell-based COVID-19 vaccine when the mRNA vaccines that are already in use are so effective? According to Kirimanjeswara, the spike protein of the SARS-CoV-2 virus is under heavy selection pressure, which can result in mutations that drive the emergence of new variant...
Ed Cohen, PharmD, FAPhA: As we look into the different types of COVID-19 vaccines, can you briefly discuss the differences and how the vaccines available might impact decisions to get a COVID-19 vaccine? Wesley Nuffer, PharmD, BCPS, CDCES: Absolutely. Mary, you make some excellent poi...